Brookline Capital Acquisition Corp. (BCAC) to Combine with Apexigen in $205M Deal
Brookline (NASDAQ:BCAC) has entered into a definitive agreement to combine with Apexigen at a net-equity value of $205 million. San Carlos, California-based Apexigen is developing a range of immunological cancer treatments with four currently in Phase II trials. The combined company is expected to trade on the Nasdaq under the symbol “APGN” once the dealRead More